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TraditionalIndianmedicine—Ayurveda—classiﬁesthehumanpopulationintothreemajorconstituentsorPrakriti knownasVata,
Pitta and Kapha types. Earlier, we have demonstrated a proof of concept to support genetic basis for Prakriti. The descriptions in
Ayurveda indicate that individuals with Pitta Prakriti are fast metabolizers while those of Kapha Prakriti are slow metabolizers.
We hypothesized that diﬀerent Prakriti may have diﬀerent drug metabolism rates associated with drug metabolizing enzyme
(DME) polymorphism.We did CYP2C19 (PhaseI DME) genotyping in 132 unrelated healthy subjects of either sex by polymerase
chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. We observed signiﬁcant association between
CYP2C19 genotype and major classes of Prakriti types. The extensive metabolizer (EM) genotype (∗1/∗1, ∗1/∗2, ∗1/∗3)w a sf o u n d
to be predominant in Pitta Prakriti (91%). Genotype (∗1/∗3) speciﬁc for EM group was present only in Pitta Prakriti. Poor
metabolizer (PM) genotype (∗2/∗2, ∗2/∗3, ∗3/∗3) was highest (31%) in Kapha Prakriti when compared with Vata (12%) and Pitta
Prakriti (9%). Genotype (∗2/∗3) which is typical for PM group was signiﬁcant in Kapha Prakriti (odds ratio = 3.5, P = .008). We
observed interesting correlations between CYP2C19 genotypes and Prakriti with fast and slow metabolism being one of the major
distinguishing and diﬀerentiating characteristics. These observations are likely to have signiﬁcant impact on phenotype-genotype
correlation, drug discovery, pharmacogenomicsand personalized medicine.
1.Introduction
Ayurveda remains one of the most ancient and yet living
traditions documented and practiced widely in India [1].
It has a time-honored philosophical and experiential basis.
The core concept of health and disease in Ayurveda is
built around the uniqueness of an individual [2]. Ayurveda
uses a 3-fold classiﬁcation known as tridosha theory that
identiﬁes principles of motion (Vata), metabolism (Pitta)
and structure (Kapha) as discrete phenotypic groupings
[3]. According to Ayurveda, the individual constitution or
Prakriti classiﬁcation is based on diﬀerences in physical,
physiological and psychological characteristics and is inde-
pendent of racial, ethnic or geographical considerations.
The importance of such individual variations in health and
disease is an important basic principle rightly described
hundreds of years ago as “every individual is diﬀerent from
another and hence should be considered as a diﬀerent
entity; as many variations are there in the Universe, all are
seen in the human being” [4–6]. The doshas exhibit more
easily recognizable phenotypes. Evidence-based research in
Ayurveda is receiving larger acceptance in India and abroad
[7–9].
According to Ayurveda, Prakriti of an individual is
determined at the time of conception and remains unaltered
during the lifetime. Prakriti-speciﬁc treatment including
medicine, diet and lifestyle is a distinctive feature of
Ayurveda [10]. We hypothesized that Prakriti has a genetic
connotation that can provide a tool for classifying human
population based on broad phenotype clusters. We hypoth-
esize that the human phenome based on Ayurveda can
provide a genetic basis for the three major constitutions or
Prakriti. Earlier, in a pilot study, we evaluated 76 subjects
both for their Prakriti and HLA DRB1 typing. We observed
a signiﬁcant correlation between certain HLA types and
Prakriti types [11]. For better validation, the homologous2 Evidence-Based Complementary and Alternative Medicine
relation of Vata (V), Pitta (P) and Kapha (K) to human
genetic structure requires further study [12].
Three major constitution types as Vata, Pitta and Kapha
Prakriti have unique putative metabolic activities. Kapha
is slow, Pitta is fast, while Vata is considered to have
variable metabolism. We hypothesize that this may relate
to drug metabolism and genetic polymorphism of drug
metabolizing enzymes (DME).Inter-individual variability in
drug response can be attributed to polymorphism in genes
encoding diﬀerent DMEs, drug transporters and enzymes
involved in DNA biosynthesis and repair [13, 14]. Mutation
in gene coding for DMEs may result in variants with high,
low or no activity. Major genetic polymorphisms aﬀecting
DME activity are related to drug oxidation by cytochrome
P450 enzymes (CYP) 2C19, 2C9 and 2D6 [15, 16]. Such
polymorphism gives rise to important inter-individual and
inter-ethnic variability in the metabolism and disposition of
several therapeutic agents resulting in diﬀerences in clinical
response to these drugs.
The CYP2C19 geneis one ofthe membersof cytochrome
P-450 (CYP) super family enzymes involved in metabolism
of a number of drugs [15, 17] and accounts for about 2% of
oxidative drug metabolism in humans [18]. In the context
of this paper, it is important to understand how genetic
factors inﬂuence CYP2C19 levels and activities. Among the
25 variants of CYP2C19, two principle alleles CYP2C19∗2
and CYP2C19∗3 have been reported with Poor Metabolizer
(PM) phenotype in Caucasians and Asian populations [19,
20]. The presence of the CYP2C19∗2 alleles leads to an
aberrant splice site, whereas the CYP2C19∗3 allele produces
a premature stop codon [21]. The importance of this
polymorphism has recently been shown as diﬀerences in
omeprazole concentrations and gastric acid suppression in
poor and extensive metabolizers (EMs) of CYP2C19 [22].
Individualswithhomozygous(∗1/∗1)orheterozygous(∗1/∗2,
∗1/∗3) wild-type CYP2C19∗1 genotype have eﬃcient enzyme
to metabolize CYP2C19 substrates and are EMs. Individuals
with homozygous (∗2/∗2, ∗3/∗3) or heterozygous mutant
CYP2C19∗2/CYP2C19∗3 genotype have reduced enzyme
activity and are termed as PMs.
We chose the CYP2C19 gene polymorphism to study
inter-individual variability in drug metabolism and its possi-
ble association with metabolically polymorphic Prakriti.W e
investigated the distribution of CYP2C19 genotypes in 132
healthy individuals with diﬀerent Prakriti classes using PCR-
RFLP technique. Our study observes an association between
CYP2C19 genotype and Ayurveda-based constitution or
Prakriti.
2.Methods
2.1. Prakriti Evaluation. The Prakriti of each subject was
assessed using a validated questionnaire based on physical,
physiological and psychological characteristics, and clinical
judgmentofseniorAyurvedicexperts.Physique,skintexture,
hunger, thirst, digestive capacity, temperament and memory
are some of the attributes evaluated to determine individual
constitution. The questionnaire also considered information
regarding ethnicity, maternal and paternal family history
of diseases, past history related to diseases, allergies and
dietary habits. Predominant Prakriti was allotted if ≥70%
dominance of a single Dosha score was obtained. Only
individuals with predominance of either of V, P or K
were included in the study. Each subject was also assessed
clinically by an Ayurvedic expert physician or Vaidya who
independently classiﬁed all subjects into V, P or K groups.
Finally, subjects were recruited in this study only when 80%
concordance was observed between Prakriti assessment with
questionnaire scores and clinical evaluation by Vaidya.T h e
borderline cases were referred to additional senior Vaidya
whose decision was considered ﬁnal.
2.2. Subject Screening and Study Population. The study was
conducted among the Maharashtrian population residing
in Western India and belonging to Australoid-Europoid
origin [23]. This avoided any confounding factors due to
population stratiﬁcation. Total 489 subjects were screened
and 167 subjects having predominant Prakriti types were
identiﬁed. Subsequently, from these 167 subjects a total of
132 unrelated ethnically matched healthy subjects of both
sexes (62 males and 70 females) with predominance of either
V (26 subjects), P (43) or K (63) were recruited for the
genotyping study, with a mean age of 23.22 (SD 5.3) years.
The study protocol was approved by the Ethics Committee
of Interdisciplinary School of Health Sciences, University of
Pune, India, and written informed consent was obtained
from all subjects.
2.3. Genotyping for CYP2C19. About 5mL of venous blood
was drawn from each subject in a vacutainer containing
EDTA as an anticoagulant. DNA was extracted using Miller’s
protocol[24].GenotypingofextractedDNAforCYP2C19∗1,
CYP2C19∗2 and CYP2C19∗3 alleles was done using the PCR-
RFLP technique as reported earlier [25]. Samples containing
mutants were reanalyzed to ensure that the method was
100% reproducible and accurate.
2.4. Statistical Analysis. Statistical analysis was performed
using the Graph Pad Prism statistical software (San Diego,
CA, USA). Using available CYP2C19 genotype data, geno-
type frequencies were calculated and 2 × 2c o n t i n g e n c y
tables were constructed using one Prakriti group against the
remaining two groups. Data related to CYP2C19 genotype
and three Prakriti types was analyzed using Fisher’s exact
probability test as the number of individuals in some of the
Prakriti classes having a particular genotype was very small.
3.Results
3.1. Prakriti Distribution. A total of 132 subjects were
classiﬁed in three major categories of Prakriti: 63 (47.7%) of
K, 43 (32.6%) of P and 26 (19.7%) of V.
3.2. CYP2C19 Genotype Distribution in Prakriti Classes. The
genotype frequencies of CYP2C19 polymorphisms in V,
Pa n dKPrakriti are presented in Table 1.T h eg e n o t y p i cEvidence-Based Complementary and Alternative Medicine 3
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Table 1: Genotype frequencies of CYP2C19 gene polymorphism in V, P and K Prakriti.
CYP2C19 Genotype Phenotype frequency P Phenotype frequency P Phenotype frequency P
Vata
n = 26 (%)
Kapha + Pitta
n = 106 (%)
Pitta
n = 43 (%)
Kapha + Vata
n = 89 (%)
Kapha
n = 63 (%)
Pitta + Vata
n = 69 (%)
1/1 11 (42.31) 34 (32.08) .360 15 (34.88) 30 (33.70) 1.000 19 (30.16) 26 (37.68) .462
1/2 12 (46.15) 47 (44.34) 1.000 22 (51.16) 37 (41.57) .351 25 (39.68) 34 (49.27) .296
1/3 — 2 (1.89) 1.000 2 (4.65) — .104 — 2 (2.89) .497
2/2 3 (11.54) 22 (20.75) .404 4 (9.32) 21 (23.59) .059 18 (28.57) 7 (10.14) .008
2/3 — 1 (0.94) 1.000 — 1 (1.12) 1.000 1 (1.59) — .477
3/3 —— — —— — —— —
repertoire in this population represents predominance of
CYP2C19 ∗1/∗2 genotype as compared to other genotypes.
This genotype was well distributed in all the three dominant
Prakriti types. EM genotype (∗1/∗1, ∗1/∗2, ∗1/∗3)w a sf o u n d
t ob ep r e d o m i n a n ti nP( 9 1 % ) .T h e∗1/∗3 genotype speciﬁc
for the EM group was present only in P. The PM genotype
(∗2/∗2, ∗2/∗3, ∗3/∗3) was highest (31%) in K when compared
with V (12%) and P (9%). CYP2C19 ∗2/∗2 genotype
frequency was signiﬁcantly higher with P value = .008 in K
type as compared to V + P types yielding an Odds Ratio of
3.5. The ∗2/∗3 genotype typical for PM group was observed
only in K Prakriti. V Prakriti did not show any signiﬁcant
association with any of the genotypes. Although our results
did not reach statistical signiﬁcance, a positive trend was
evident in Prakriti CYP2C19 genotype association.
4.Discussion
Earlier, in an exploratorystudy correlatingHLADRB1alleles
with ayurvedic Prakriti classiﬁcation, we suggested a genetic
basis for the system classiﬁcation [26]. Present study gives
preliminaryevidenceforthemetabolicvariabilityofdiﬀerent
Prakriti types using DME CYP2C19 gene polymorphism
model.
The results obtained in this study suggest possible
association of CYP2C19 gene polymorphism with Prakriti
phenotypes. We observed predominance of EM genotypes
(∗1/∗1, ∗1/∗2, ∗1/∗3)i nPPrakriti with fast metabolism. The
PM genotypes (∗2/∗2, ∗2/∗3, ∗3/∗3) were highest in K that
is expected to be metabolically slow. The CYP2C19 ∗2/∗2
genotype frequency was signiﬁcantly higher in K type as
compared to V + P types. The reported frequencies of ∗1/∗3
and ∗2/∗3 genotypes in Maharashtrian population is very
low—1.4% and 0.7%, respectively [25]. It is interesting to
note that ∗1/∗3 genotype speciﬁc for the EM group was
present only in P and ∗2/∗3 genotype typical for PM group
was observed in K, as expected. The V type did not show
any signiﬁcant association with any of the genotypes. Some
of the genotypes were common to two or more Prakriti
classes conﬁrming the overlap of doshas among Prakriti
classes (Figure 1). These results allow us to predict that K
and P being slow and fast metabolizer groups are likely to
require low and high doses of CYP2C19 substrates such
as diazepam, certain barbiturates, tricyclic antidepressants,
omeprazole and proguanil.
This exploratory study was aimed at investigating
metabolic variability in Prakriti classes and its relation with
the gene polymorphism. One of the limitations of our study
is the small sample size and hence, positive associations need
to be conﬁrmed with large sample size. Extensive studies
on Prakriti subtypes and genome wide single nucleotide
polymorphism (SNP)mapping especially ofotherimportant
DME polymorphisms like CYP2D6, CYP2C9, CYP3A4,
TPMT, and so forth, would be useful to understand possible
Prakriti pharmacogenomics relationship correlating geno-
type, Prakriti and drug metabolism. The data generated in
this study could be further supported by pharmacokinetic
studies on K and P subjects. We have initiated studies4 Evidence-Based Complementary and Alternative Medicine
on the eﬀect of Prakriti and gene polymorphism on drug
metabolism and clinical outcome in rheumatoid arthritis
patients.
Few earlier studies have attempted to address the rela-
tionship between traditional medicine constitutions and
HLA polymorphism [27–29]. Studies on whole genome
expression [30] and the pharmacogenomics of medicinal
plants [31, 32] have also been attempted. There are several
similarities between Ayurveda and the Traditional Chinese
Medicine (TCM), including the holistic and individual clas-
siﬁcation systems [33]. Genomics/proteomics correlates of
Sasang constitutionalmedicine (SCM)and Kampo medicine
have been reported recently [34–38]. Advancements in the
analytical and biological sciences, along with innovations
in genomics and proteomics can play an important role in
validation of these ancient therapies[39]. Our study demon-
strates a probable genomic basis for metabolic diﬀerences
attributed by Prakriti. Identiﬁcation of genetic variations
underlying metabolic variability in Prakriti may provide
newer approach to Pharmacogenomics.
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